Handgrip performance as a predictor of incident cognitive decline in older adults: A systematic review and meta-analysis.

Neurosci Biobehav RevJun 10, 2026 (epub)
Clinical ResearchGeriatricsNeurology

Muhammad Younis, Wouter A J Vints, Ivan Bautmans

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between handgrip performance and cognitive decline in older adults aged 45 and above. Analyzing data from 60 studies involving 380,960 participants, the findings indicated that maintaining or increasing handgrip strength is associated with a reduced risk of cognitive decline (RR=0.809).

Key findings

  • Maintained or increased handgrip strength was linked to a reduced risk of cognitive decline (RR=0.809).
  • Higher baseline handgrip strength also correlated with a lower risk of cognitive decline (RR=0.812).
  • Baseline handgrip strength showed a positive association with global cognition (SRC=0.237).

Why it matters

Identifying early predictors of cognitive decline is essential for timely interventions in aging populations. Handgrip strength may serve as a practical and clinically meaningful biomarker for assessing cognitive health.

Source

PubMed · PMID 42269958

Published in Neurosci Biobehav Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.